Reporter brief
A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The effect of metformin specifically cannot be isolated because it was used as part of multi-component treatment regimens rather than as a standalone intervention.
- Whether any observed benefits persist beyond 90 days, as this was a short-term pilot study.
- Whether the intervention improves actual lifespan or healthspan measures commonly used in aging research, as the outcomes measured are not specified in the available information.
Study design and sample
Rct; Human.
Small sample size pilot study; specific population characteristics not reported
- Design
- Rct
- Sample
- 30
- Journal
- AgelessRx
- Published
- Mar 16, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.